SAN DIEGO, — Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that it has closed a registered direct offering of $15 million of common stock at a price of $7.00 per share. The shares were sold directly to an institutional investor by the Company.

Trovagene intends to use the net proceeds from the offering to fund its research and development activities and for working capital and other general corporate purposes.

The securities described above are being offered pursuant to a shelf registration statement (File No. 333-186196), which was declared effective by the United States Securities and Exchange Commission (“SEC”) on February 4, 2013. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. When filed with the SEC, copies of the prospectus supplement and the accompanying base prospectus relating to this offering may be obtained at the SEC’s website at https://www.sec.gov.